REGN Jun 2024 1000.000 call
| Previous close | 7.80 |
| Open | 6.70 |
| Bid | 4.50 |
| Ask | 8.30 |
| Strike | 1,000.00 |
| Expiry date | 2024-06-21 |
| Day's range | 6.70 - 6.70 |
| Contract range | N/A |
| Volume | |
| Open interest | 624 |
PR NewswireBiohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, announced the first patient has been dosed in a first-in-human Phase 1/2 study of BHV-1510, a highly differentiated Trophoblast Cell Surface Antigen-2 (Trop-2) directed Antibody Drug Conjugate (ADC), and the lead ADC program to advance into clinical trials in Biohaven's g
Simply Wall St.Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution
The fact that multiple Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders offloaded a considerable amount of...
Insider MonkeyThe Biggest Biotechnology Company in Europe
We’ve recently covered a list of 20 Biggest Publicly-Traded Biotech Companies based on market caps that you can visit here. Biotechnology and Industry 2023: Market Growth, Transformations, and Technological Milestones The global biotechnology market was valued at approximately $1.55 trillion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030, reaching a staggering $3.88 trillion by 2030. The […]
